Leone, MD – CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. Epub 2008 Feb 5. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. To date, the studies Genocea Biosciences has run have not made clear how much better its experimental genital herpes vaccine is than a . . About Genocea Biosciences, Inc. The conference call may be accessed by dialing (844) 826-0619 for domestic participants and (315) 625-6883 for international callers (reference conference ID 55798395).
It was very busy, as always. Cash Position: Cash, cash equivalents and investments as of June 30, 2016 were $86.0 million compared to $95.7 million as of March 31, 2016. A webcast replay of the conference call will be available on the Genocea website beginning approximately two hours after the event, and will be archived for 30 days. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. As a result, the company shifted its focus to infectious disease vaccines. First results from this study are expected for the second half of 2017. For more information about GEN-003, please visit http://www.genocea.com/platform-pipeline/pipeline/gen003-for-genital-herpes/.
This 28-day observation period was repeated immediately after the completion of dosing and at six and, in time, twelve months following dosing. Its share price was up 31.2% in the past one year. ET. Safety in the trial is continuously reviewed by an independent Drug Monitoring Committee. Vical said it is also advancing its in-licensed antifungal compound toward a Phase I trial set to launch during the first half of 2016. Guest speaker Charles G. Holger Zimmermann.
This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. HSV-2 is a sexually transmitted virus that is the main cause of recurrent genital herpes, accounting for the majority of genital ulcerative lesions worldwide. Data should be out by the second half of 2016. Based on these studies the authors concluded that mice, like humans, generate T-cell responses against tegument protein epitopes and that these tegument proteins, together with the HSV-2 envelope glycoprotein D (gD) also evaluated in the experiments, are rational candidates for further HSV-2 vaccine research. The company expects to complete enrolment in a phase III study on ASP0113 in hematopoietic cell transplant recipients in the third quarter of 2016. Dingermann. The trial enrolled 131 subjects from 9 institutions in the United States.
All of the approved vaccines to date work in a more limited way, by only coaxing B cells to fight viruses. The Company expects to report six-month clinical efficacy data from its ongoing Phase 2b placebo-controlled trial in January 2017. It is a recurrent, lifelong viral infection. All patients were then asked to keep a diary in which they recorded any signs or symptoms and swab their genital areas each day. Moreover, the phase I/IIa study was also designed to show proof-of-concept that GEN-003 can reduce HSV-2 viral shedding. So what: The reason for the huge jump on Thursday had to do with results from a phase 2 trial for the company’s lead compound GEN-003, a drug that Genocea is studying as a potential treatment for genital herpes. (Checkmate) and US Oncology Research.
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Let’s take a look. Both prophylactic vaccines significantly reduced detectable HSV-2 infection at the dorsal root ganglia latent site. for manufacturing services performed under our ASP0113 collaborative agreements. (NASDAQ:GNCA), a company developing T cell-directed vaccines and immunotherapies today held its first R&D day for investors and analysts. The company announced positive 12-month efficacy data from its Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. 8, 2011 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today the issuance of U.S.
(NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported that it has completed enrollment in its Phase 2 dose optimization clinical trial for GEN-003 for the treatment of genital herpes. Genocea Biosciences, Inc. CAMBRIDGE, Mass.–(BUSINESS WIRE)– Genocea Biosciences, Inc. SAN DIEGO, June 13, 2016 (GLOBE NEWSWIRE) — Vical Incorporated (Nasdaq:VICL) announced today that the company will present clinical data on its completed HSV-2 Phase 1/2 trial at the American Society of Microbiology (ASM) Microbe/ICAAC 2016 conference (Boston, June 16 – 20). What: Shares of Genocea Biosciences (NASDAQ:GNCA), a small-cap biopharma developing developing T cell-directed vaccines and immunotherapies, dropped by over 10% in August, which was pretty much right in line with the drop in the broader biotech sector. Although cancer grabs the spotlight for harnessing the immune system against tumors, other therapeutic areas and modalities are being developed in the shadows. Genocea Biosciences, Inc.
Genocea Biosciences, Inc. What: Shares of Genocea Biosciences (NASDAQ:GNCA), a biotech company with a focus on vaccines and immunotherapies, fell more than 10% today before moderating back to a 7% loss after the company announced the pricing of its recently announced $50 million public offering.